Skip to main content

Table 2 Differences between study variables from 6 months prior to enrollment, baseline and month 6

From: Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis

Factor

6 Months prior to enrollment

Baseline

Month 6

95% CI for changes

6 Months prior to enrollment to baseline

Baseline to month 6

[Mean ± SD]

[Mean ± SD]

[Mean ± SD]

 

P value

P value

ETDRS BCVA

70.1 ± 7.7

70.0 ± 7.2

71.5 ± 8.9

1.55 (− 2.08, 5.18)

0.95

0.38

Central subfield thickness (µm)

420.8 ± 100.5

419.7 ± 92.0

303.8 ± 73.1

− 116.0 (− 150.8, − 81.15)

0.99

<  0.001

Cube volume (mm3)

N/A

11.5 ± 1.4

10.7 ± 1.2

− 0.86 (− 1.06, − 0.65)

N/A

<  0.001

Cube average thickness (µm)

N/A

320.7 ± 38.6

297.2 ± 33.1

− 23.50 (− 29.36, − 17.64)

N/A

<  0.001

Foveal avascular zone (mm2)

N/A

0.31 ± 0.13

0.33 ± 0.11a

− 0.03(− 0.11, 0.05)

N/A

0.47

  1. Statistically significant values are in bold italic
  2. ETDRS early treatment diabetic retinopaty study, BCVA best corrected visual acuity, CI confidence interval
  3. an = 18